Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Abstract

Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1 + ARA-C on days 1--5; R 2 = courses of daunorubicin on days 1 and 2 + ARA-C on days 4--8; R 3 = courses of daunorubicin-DNA complex on days 1--2 + ARA-C on days 4--8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.

• Authors: G Gahrton, M Björkholm, G Brenning, I Christenson, L Engstedt, S Franzén, B Gullbring, G Holm, C Högman, P Hörnsten, S Jameson, A Killander, C Simonsson-Lindemalm, D Lockner, B Lönnqvist, H Mellstedt, J Palmblad, C Paul, C Pauli, C Peterson, P Reizenstein, B Simonsson, K O Skårberg, A M Udén, B Wadman
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 2 Issue 1 Pg. 73-6 ( 1979) ISSN: 0344-5704 [Print] Germany
• PMID: 498423 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• DNA
• Daunorubicin

Topics

• Acute Disease
• DNA (adverse effects, therapeutic use)
• Daunorubicin (adverse effects, therapeutic use)
• Evaluation Studies as Topic
• Humans
• Leukemia (drug therapy)
• Middle Aged
• Time Factors